ASH: Positive findings for BeiGene's tislelizumab in Hodgkin's lymphoma

China’s biopharma firm BeiGene (Nasdaq: BGNE) clinical data from the pivotal Phase II trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL), at the Annual Meeting of the American Society of Hematology (ASH) yesterday.

These data are included in BeiGene’s new drug application (NDA) in China for tislelizumab for the treatment of patients with R/R cHL. They also add to BeiGene’s earlier encouraging and much anticipated presentation at the ASH meeting on its  zanubrutinib in patients with mantle cell lymphoma.

“We set out to address the needs of patients with R/R cHL who have failed to achieve a response or progressed after autologous stem cell transplant (ASCT), or who are not candidates for ASCT, as these patients, unfortunately, have very poor outcomes,” said Dr Jane Huang, chief medical officer, hematology, at BeiGene. “We are excited to report strong results including high complete response (CR) rates from the first registration study for this potentially differentiated anti-PD-1 agent,” she added.